Pediatrics
Conference Coverage
New RSV vaccine will cut hospitalizations, study shows
With widespread use of the vaccine, annual hospitalizations resulting from infant RSV would fall by 51%, emergency department encounters would...
News
New guidelines for determining brain death released
For the first time, the guidance clarifies that clinicians don’t need to obtain consent before performing a brain death evaluation, unless...
Latest News
3-D stereophotogrammetry helps detect progression of craniofacial morphea
Existing tools that detect disease progression in patients with CM are limited.
From the Journals
Pediatric sleep-disordered breathing linked to multilevel risk factors
Exposure to indoor pests, maternal education, and neighborhood factors play into sleep-disordered breathing–related symptoms.
Latest News
Pediatric psoriasis: Black children, males more likely to have palmoplantar subtype, study finds
Nail involvement occurred in significantly more Black and Hispanic/Latino patients than in White patients.
News
The influence of social media on adolescents seeking autism diagnoses
It is important to take time to understand the drive behind an adolescent’s apparent desire for a specific diagnosis, particularly if that...
Latest News
Patch testing finds higher prevalence of ACD among children with AD
AD and ACD both present with red, itchy, eczema-like patches and plaques and can be “really hard to differentiate.”
From the Journals
ADHD rates holding steady in U.S. children
The estimated ADHD prevalence remains “high” and “further investigation is warranted to assess potentially modifiable risk factors and provide...
News from the FDA/CDC
Intravenous formulation of secukinumab gets FDA approval
This new route of administration is expected to become available during the fourth quarter of 2023.
From the Journals
Maternal pertussis vax effective for infants in most vulnerable months
Large study also helps answer questions on duration of effectiveness and the potential “blunting” effect in infants.
Latest News
FDA approves topical roflumilast for psoriasis in children aged 6-11
Topical roflumilast was first approved in July 2022 for individuals aged 12 and older.